A new therapeutic class for the therapy of type 2 diabetes: DPP-4 inhibitors (sitagliptin);Új kezelési lehetoség a 2-es típusú diabetes terápiájában: DPP-4-gátlók (sitagliptin)

Orvosi Hetilap

Volumn 151, Issue 25, 2010, Pages 1012-1016

  Ábel, Tatjána ^a   Fehér, János ^b  

^a Szakrendelo Intézet ^*  (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Incretin; Sitagliptin; Therapy

Indexed keywords

GLIMEPIRIDE; GLIPIZIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SHORT SURVEY; SIDE EFFECT; WEIGHT GAIN; BLOOD; CELL PROLIFERATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; METABOLISM; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; REVIEW;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; PYRAZINES; TRIAZOLES;

EID: 77953208938     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28910     Document Type: Short Survey

References (20)

1. DeFronzo, R. A:. From the triumvirate to the ominosus octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 2009, 58, 773-795.
2. A Magyar Diabetes Társaság szakmai irányelve. Diabetol. Hung., 2009, 17, 23-28.
3. Drucker, D. J., Sherman, S. I., Gorelick, F. S és mtsai: Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care, 2010, 33, 428-433.
4. Gero L.: Klinikai eredmények dipeptidil-peptidáz-4 gátló gyógy-szerekkel. Diabetol. Hung., 2008, 16, 261-272.
5. Halmos T.: Új lehetoség a 2-es típusú diabetes mellitus kezelésében. DPP-IV inhibitorok és inkretinmimetikumok. Metabol., 2007, 5, 77-80.
6. Jermendy Gy.: Az inkretin-hatáson alapuló terápia hatékony-sága és biztonságossága 2-es típusú diabetesben. Metabol., 2007, 6, 137-139.
7. Winkler G.: Inkretin hatáserosítok, inkretin mimetikumok - a terápiás alkalmazás kigondolásától a gyakorlati megvalósí-tásig. Orv. Hetil., 2007, 148, 579-587.
8. Thornberry, N. A., Gallwitz, B.: Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism, 2009, 23, 479-486.
9. Nauck, M. A., Vilsboll, T., Gallwitz, B. és mtsai: Incretin-based therapies. Diabetes Care, 2009, 32, S223-S231.
10. Davidson, J. A.: Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve. Clin. J. Med., 2009, 76, S28-S38.
11. Nauck, M. A., Meininger, G., Sheng, D. és mtsai: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab., 2007, 9, 194-205.
12. Williams-Herman, D., Round, E., Swern, A. és mtsai: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders, 2008, 8, 14-29.
13. Blonde, L.: Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleveland Clinic Journal of Medicine, 2009, 76, S4-S11.
14. Nauck, M., Smith, U.: Incretin-based therapy: How do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients? Best Practice & Research Clinical Endocrinology & Metabolism, 2009, 23, 513-523.
15. Farilla, L., Hui, H., Bertolotto, C. és mtsai: Glucagon-like pep-tide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology, 2002, 143, 4397-4408.
16. Mu, J., Petrov, A., Eiermann, G. J. és mtsai: Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. European Journal of Pharmacology, 2009, 623, 148-154.
17. Brazg, R., Xu, L., Man, C. M. és mtsai: Effect of adding sitaglip-tin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycemic control and β-cell function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2007, 9, 186-193.
18. Nikolaidis, L. A., Mankad, S., Sokos, G. G. és mtsai: Effects of glucagon-like peptid-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reper-fusion. Circulation, 2004, 109, 962-965.
19. Bose, A. K., Mocanu, M. M., Carr, R. D. és mtsai: Glucagon-like peptid 1 can directly protect the heart against ischemia/reper-fusion injury. Diabetes, 2005, 54, 146-151.
20. Nikolaidis, L. A., Elahi, D., Hentosz, T. és mtsai: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation, 2004, 110, 955-961.